Aptose Biosciences to Present at Canaccord Genuity Rare Disease Biopharma 1×1 Day

SAN DIEGO and TORONTO, Feb. 02, 2017 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer and Gregory Chow, Senior Vice President and Chief Financial Officer, will participate in the upcoming Canaccord Genuity Rare Disease Biopharma 1×1 Day to be held on February 6, 2017 at the InterContinental Barclay Hotel, New York, NY. 

About Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with companion diagnostics to identify the optimal patient population for our products. The company’s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.

CONTACT: For further information, please contact:

Aptose Biosciences
Greg Chow, CFO

SMP Communications
Susan Pietropaolo